AFP and Cirrhosis: At baseline, patient 8 was free active disease but positive for cirrhosis, had normal AFP (5 ng/ml), had Karnofsky performance status 80%, was Child-Pugh A, HLA-A2+, and had intermediate detectable levels of anti-AdV neutralizing antibodies which were in the acceptable range for trial enrollment.